Role of Fibrocytes in Chronic Obstructive Pulmonary Disease

Study Overview
=================
Brief Summary
-----------------
Chronic obstructive pulmonary disease (COPD) is a frequent airway disease characterized by both bronchial inflammation and remodelling. Bronchial mucosa is infiltrated by macrophages, neutrophils and lymphocytes. In addition, the number of eosinophils can be also increased during exacerbation. Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of COPD and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.

Official Title
-----------------
Role of Fibrocytes in the Bronchial Remodeling of Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Procedure: blood sample
* Procedure: Clinical and functional evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients: diagnostic of Chronic obstructive pulmonary disease (COPD) exacerbation. Control group: subjects without any history of lung disease and with normal lung function testing. Subjects will be separated in 2 sub-groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex. Written informed consent Exclusion Criteria: Subject without any social security or health insurance Asthma, lung fibrosis or idiopathic pulmonary hypertension Chronic viral infections (hepatitis, HIV)

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic obstructive pulmonary disease patients<br>COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux. Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis. | Procedure: blood sample<br>* blood sample for fibrocytes analysis<br>Procedure: Clinical and functional evaluation<br>* Plethysmography, Carbon monoxide capacity of transfer , arterial gaz<br>|
| Control group<br>Subjects without any history of lung disease and with normal lung function testing | Procedure: blood sample<br>* blood sample for fibrocytes analysis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of circulating blood fibrocytes | Sampling of blood in Chronic obstructive pulmonary disease patients | Day 1 | 
| Number of circulating blood fibrocytes | Sampling of blood in Chronic obstructive pulmonary disease patients | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterization of fibrocytes | Sampling of blood | Day 1 and at 2 months | 
| Differenciation of blood fibrocytes | Sampling of blood | Day 1 and at 2 months | 
| Chemotactism of blood fibrocytes | Sampling of blood | Day 1 and at 2 months | 
| Number of exacerbation |  | 12 months after V2 | 
| Mortality |  | 12 months after V2 | 
| Annual decline of ventilatory function |  | 12 months after V2 |